Ciancio 2012 — HCV Non-Responder Phase 3

Journal of Viral Hepatitis

Ciancio A, Andreone P, Kaiser S, et al.

Summary

ITT SVR 12.7% vs 10.5% placebo, P=0.41 — NEGATIVE

Study Details

Study Design

Phase 3 multicenter double-blind RCT

Indication

Chronic hepatitis C non-responders

Intervention

1.6 mg twice weekly SC

Species

Human

Sample Size

552 subjects

Risk of Bias Assessment

Low risk of bias; standard Phase 3 design; ITT negative